Veritas Pharma Inc.: Q2 ’19
Included in this report:
• Cannin Tools
• Market & Industry Update
• Fundamental Analysis (Veritas Pharma Inc.)
• Medical Research
• Cannabis Terminology
• Hemp Infographic
• Industry Terminology
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company whose 100% owned subsidiary Cannevert Therapeutics Ltd. is attempting to advance the science behind medical cannabis. It aims to develop cannabis strains with proven scientific evidence of efficacy for pain, nausea, epilepsy and PTSD, solving a need for clinical data to support medical marijuana claims.
CTL uses a low-cost R&D model to drive value and speed-to-market. Its management team consists of veteran academic pharmacologists, anesthetists & chemists. The company plans to patent IP strains and sell or license them to cancer clinics, insurance industry and pharma, targeting a multi-billion-dollar market.
Through over 250 experiments, and over 150 pharmacological and biological studies, it has discovered two cannabis strains as potentially therapeutic—one for pain and the other for nausea.
It plans to soon begin generating revenue by offering cannabis chemical, biological and pharmacological testing services to Licensed Producers to determine the clinical utility of their cannabis strains from batch to batch. CTL is developing processes to test cannabis for cannabinoids, microbes, terpenes, toxins, metals, residual solvents and pesticides.
Veritas was formerly known as Seashore Organic Medicine Inc. and changed its name to Veritas Pharma Inc. in December 2015.